Business
Sutro Biopharma to Host Conference Call on April 27, 2020, to Provide Clinical Update on its STRO-002 Antibody-Drug Conjugate
- Company to present updated STRO-002 data at AACR Virtual Annual Meeting - SOUTH SAN FRANCISCO, Calif., April 20, 2020 /PRNewswire/ -- Sutro Biopharma, Inc.
About this update from Sutro Biopharma, Inc.
[{"type":"text","content":"- Company to present updated STRO-002 data at AACR Virtual Annual Meeting -\n\n\nSOUTH SAN FRANCISCO, Calif., April 20, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, will host a conference call and live audio webcast on Monday, April 27, at 8 a.m. EDT to discuss updated dose escalation safety and efficacy data from the company's ongoing Phase I study of STRO-002 in ovarian and endometrial cancer that is being presented as a virtual poster at the AACR Virtual Annual Meeting. The virtual poster will be accompanied by a video presentation from Dr. Wendel Naumann of The Levine Cancer Institute. \nSTRO-002 is a novel antibody-drug conjugate (ADC) targeting the clinically validated folate receptor-α (FolRα), an antigen known to be overexpressed in ovarian cancer. Sutro discovered, developed and manufactures STRO-002 using its proprietary XpressCF+™ cell-free protein synthesis technology.\nConference Call Information:\nTo access the conference call and live audio webcast on Monday, April 27, at 8 a.m. EDT, please dial (833) 729-4781 (domestic) or (830) 213-7705 (international) and refer to conference ID 2699785.\nThe conference call will be webcast via the Investors page on the Company's website at ir.sutrobio.com. Approximately two hours following the live event, a webcast replay of the conference call will be available through the Company Presentation page of the Investor section of the company's website at www.sutrobio.com for approximately 30 days.\nPoster Presentation Details:\nSTRO-002-GM1, a First in Human, Phase 1 Study of STRO-002, an anti-Folate Receptor-alpha (FRα) Antibody Drug Conjugate (ADC), in Patients with Advanced Platinum-Resistant/Refractory Epithelial Ovarian Cancer (OC), including Fallopian Tube or Primary Peritoneal Cancers\nDate & Time: \nMonday, April 27, 2020, 9:00 a.m. to 6:00 p.m. EDT\nLocation: \nThe AACR Virtual Meeting at aacr.org\nPoster Number: \nCT125\nThe submitted abstract and the virtual poster presentation will also be accessible through the Clinical/Scientific Presentation and Publication Highlights page of the News section of the company's website at www.sutrobio.com on the day of the pres...